Medicus Pharma MDCX 深 滬
等待開盤 09-17 09:30:00 美东时间
0.1562
+0.004
+2.70%
華盛通- 最 高0.1598
- 今 開0.1501
- 成交量 329.10万股
- 最 低 0.1501
- 昨 收 0.1521
- 總市值 1120.11万
- 52周最高 2.78
- 市盈率 靜 --
- 換手率 4.59%
- 52周最低 0.144
- 委 比 14.50%
- 總股本 7171.00万
- 歷史最高 8.94
- 量 比 0.47
- 振 幅 6.38%
- 歷史最低 0.144
- 每 手 1
- 風險率 0.85%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Medicus Pharma And Yorkville Mutually Agree To Terminate Standby Equity Purchase Agreement For Up To $15M Of Stock
On September 11, 2026, Medicus Pharma Ltd. (the "Company") and YA II PN, LTD. ("Yorkville") mutually agreed to terminate the Standby Equity Purchase Agreement, dated as of February 10, 2025, between the Company and Yorkville (the "SEPA"), effective as of such date. Pursuant to the SEPA, the Company ...
09-14 20:13
430亿美元买入、10亿美元卖掉，亏吗？
（来源：抗体圈） 刚刚，辉瑞与加拿大生物技术公司Medicus Pharma达成了一项最高可达10亿美元的授权协议。 被摆上货架的，是今年3月刚刚被辉...
09-04 17:23
超10亿美元！辉瑞终止的CD228 ADC获新东家
（来源：药研网） 9月3日，Medicus Pharma向美国SEC提交文件披露，公司通过其全资子公司Medicus Pharma Inc.，与辉瑞...
09-04 17:14
辉瑞曾放弃的这款药，正在逆袭！
近日，辉瑞与加拿大小型生物科技公司Medicus Pharma达成了一项共同开发与许可协议，将此前已终止研发的ADC候选药物PF-08046031（又名CD2...
09-04 16:34
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Medicus Pharma Ltd. (NASDAQ:MDCX) secured on Wednesday an exclusive, sublicensable global license from Pfizer Inc. (NYSE:PFE) to develop, manufacture, and commercialize PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate targeting melanotransferrin. • Medicus Pharma stock is testin...
09-04 01:17
Medicus Pharma Secures Global Pfizer License for CD228V
Medicus Pharma Ltd ( ($MDCX) ) just unveiled an update. On September 2, 2026, M...
09-03 20:51
Quant Check: Top- and bottom-rated small-cap healthcare stocks post-earnings
As earnings season ends, investors are turning to updated Quant ratings to see how companies stack up after their latest results. These ratings grade stocks on key metrics like value, growth, profits,...
09-01 22:25
Medicus Pharma GAAP EPS of -$0.21
Medicus Pharma press release (MDCX): Q2 GAAP EPS of -$0.21. Cash, cash equivalents, and restricted cash: $25.2M as of June 30, 2026. More on Medicus Pharma Ltd. Seeking Alpha’s Quant Rating on Medicus...
08-13 22:38
Medicus Pharma Q2 EPS $(0.21) Misses $(0.13) Estimate
Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.13) by 61.54 percent. This is a 51.16 percent increase over losses of $(0.43) per share from the same period last year.
08-13 06:02
Medicus Pharma Receives FDA's Study May Proceed Letter Authorization For Its Investigational New Drug For SKNJCT-005 To Start Phase 2b Clinical Study To Treat Gorlin Syndrome
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that the U.S. Food and Drug Administration ("FDA") has completed its safety r...
07-27 20:18
